LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only. If serial monitoring is required, please use the serial monitoring number 480129 to order.
4 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Serum or plasma
Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube
If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.
LASA is a useful adjunct in the management of a variety of malignancies. It is generally used in conjunction with other tumor markers.
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
8 - 23 mg/dL
Elevations in blood LASA levels have been reported in patients with mammary (63%), gastroenteric (65%), pulmonary (79%), and ovarian (94%) neoplasms as well as those with leukemia (86%), lymphoma (87%), melanoma (84%), sarcoma (97%), and Hodgkin disease (91%). LASA levels can also be elevated in patients with certain benign diseases, including inflammatory disorders. Thus, like carcinoembryonic antigen (CEA), the assay for LASA does not have the specificity or sensitivity necessary for cancer detection. However, recent studies have suggested that LASA levels may be useful in monitoring the course of therapy and detecting disease recurrence in certain cancer patients. In patients with mammary, ovarian, or colorectal neoplasms, a correlation has been found between LASA concentrations and therapeutic responses. Measurement of pre- and post-treatment LASA levels is advocated for determining a baseline for therapeutic monitoring. The combination of LASA and CEA measurements in patients with mammary, colorectal, or pulmonary cancer, and LASA and cancer antigen 125 (CA 125) measurements in those with ovarian cancer may improve the accuracy of assessing therapeutic responses. Preliminary studies have demonstrated that LASA concentrations are indicative of disease status in patients with leukemia, lymphoma, or cancer of the breast, ovary, or colorectum.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|100313||Lipid-associated Sialic Acid||2943-9||100313||Lipid-associated Sialic Acid||mg/dL||2943-9|
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf